Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.
about
Defining the sister rat mammary tumor cell lines HH-16 cl.2/1 and HH-16.cl.4 as an in vitro cell model for Erbb2Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyEpigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidineAn update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesA Perspective on the Comparative Antileukemic Activity of 5-Aza-2'-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza)Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancerMolecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?Active DNA demethylation in post-mitotic neurons: a reason for optimismHistone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and preventionDNA demethylation and invasive cancer: implications for therapeuticsEpi-fingerprinting and epi-interventions for improved crop production and food qualityDirect but no transgenerational effects of decitabine and vorinostat on male fertilityCETSA screening identifies known and novel thymidylate synthase inhibitors and slow intracellular activation of 5-fluorouracil.Comprehensive DNA methylation analysis of the Aedes aegypti genomeThe quest for an effective and safe personalized cell therapy using epigenetic toolsThe impact of the Cancer Genome Atlas on lung cancer.Analysis of DNA methylation and gene expression in radiation-resistant head and neck tumorsAzacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell linesMolecular modeling studies of the novel inhibitors of DNA methyltransferases SGI-1027 and CBC12: implications for the mechanism of inhibition of DNMTsEmbryonic carcinoma cells show specific dielectric resistance profiles during induced differentiationFunctional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML)A genome-wide search for epigenetically [corrected] regulated genes in zebra finch using MethylCap-seq and RNA-seqSystematic discovery of drug action mechanisms by an integrated chemical genomics approach: identification of functional disparities between azacytidine and decitabineThe cancer-associated CTCFL/BORIS protein targets multiple classes of genomic repeats, with a distinct binding and functional preference for humanoid-specific SVA transposable elementsStructural diversity of the epigenetics pocketome.Coupling sequence-specific recognition to DNA modification.Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study.Global demethylation of rat chondrosarcoma cells after treatment with 5-aza-2'-deoxycytidine results in increased tumorigenicityDifferential DNA methylation at conserved non-genic elements and evidence for transgenerational inheritance following developmental exposure to mono(2-ethylhexyl) phthalate and 5-azacytidine in zebrafishThe role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.Novel targeted therapeutics for metastatic castration-resistant prostate cancer.Demethylating Agents in the Treatment of CancerGemcitabine functions epigenetically by inhibiting repair mediated DNA demethylation.Role of Ucp1 enhancer methylation and chromatin remodelling in the control of Ucp1 expression in murine adipose tissueC5-DNA methyltransferase inhibitors: from screening to effects on zebrafish embryo development.In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia.Epigenetic modulation of intestinal cholesterol transporter Niemann-Pick C1-like 1 (NPC1L1) gene expression by DNA methylation.A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancerMolecular and enzymatic profiles of mammalian DNA methyltransferases: structures and targets for drugs.Epigenetic control of gene function in schistosomes: a source of therapeutic targets?
P2860
Q21134904-12B9FD23-F39B-4CEA-8830-825865672CF0Q24563021-5F1A0BA5-CA9E-40B1-930A-15CCD44492E5Q24608659-A30F731E-7849-4B97-B67A-DB4ACC3BA086Q24622700-8E71A9B9-2D25-449D-8F40-D3A6095E94F6Q24628329-8C149945-AA4D-4CC7-BB41-C58D5024EB7FQ24642847-695CD9DA-4DB5-47DC-97AC-E626A8C206FAQ26801573-AFD08CFD-AE67-4A14-A0B7-457AE81680AEQ26829515-4BA388AE-A0E5-4585-87C5-EBD0AD00D0DBQ26994739-B8FBA693-DA30-4195-9698-556F787EED18Q27011914-35C7C6EB-992C-400D-8F60-847041063797Q27022692-840CD208-63F7-42E0-8408-109E026238DDQ27315154-E9910E9C-5481-44C9-9368-54AE8AA21557Q27323225-191C4E9F-09A2-4B90-A56F-0F5D860E92A7Q27928034-FCCE8E39-9553-4D53-AE87-6290B6E9DE73Q28079389-A808EDB6-7BC4-410C-ABF6-FB3AC94C34DAQ28084190-61B635D4-BD41-41C9-95AA-FD320C802B82Q28392236-A70A2F8D-AB32-4EAE-9098-4181FA28197BQ28477342-9DB65A0F-506B-4E33-9F0D-E5C3FFE58678Q28487027-6BDBFE12-20AA-43C2-94EE-103C5FE1E129Q28488736-2A52651A-0D93-4ECE-B78B-2B55608F7C7CQ28546856-F550D0AE-81F2-442E-BC50-9E4A9A3F9273Q28600970-DB8E6615-0037-4F45-8FF2-554BC93AF4A5Q28822412-83D1D7F1-86AF-42BF-BFF6-97AAE21882C6Q28828237-25FBEE06-091B-4F76-BCED-044E061EAF2AQ30487951-4457BFE1-9DF7-4192-89FB-6D8F2E152AD5Q30490702-CD2B52D5-FA39-469E-9919-736B57F590B4Q33396282-6A7177CE-ED95-45B3-A7D9-8032352566AFQ33519525-09B1669F-7EDF-4B57-AC79-ABC2B1B314D0Q33556422-2B57AB79-F71C-497A-A692-31A2CB86844BQ33578787-50B0A99E-1F95-44E7-8861-8E799CE8F392Q33642278-BB948857-2FED-4637-B289-1291476A58C0Q33678040-53D641C1-E042-4322-B493-F4C5D9F565ABQ33761140-DEA8E7D4-1E26-497E-9C7B-E51959833AF0Q33814183-46CD2C87-BF85-487E-BC2F-46997297849CQ33919923-50F62E88-CAE1-415F-B2F8-58F7B8481DCAQ33997187-3F10F13E-2C56-4887-A9E6-058A1B186CCCQ34044763-12E602C4-861D-4D3A-A101-BCA4473D394DQ34091420-9DA21AF1-B9F1-4328-8F4C-29FFC6546695Q34143019-58D78BC9-4B06-4E0C-B70C-6502F3E77F5DQ34159188-B62A42F4-D141-4A28-A646-F9D471EE9CC4
P2860
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.
@ast
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.
@en
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.
@nl
type
label
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.
@ast
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.
@en
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.
@nl
prefLabel
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.
@ast
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.
@en
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.
@nl
P356
P1476
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine
@en
P2093
Frank Lyko
P356
10.1002/IJC.23607
P577
2008-07-01T00:00:00Z